WASHINGTON, March 20, 2012 /PRNewswire-iReach/ -- FirstMark today announced further results from the completed clinical study for the multiple biomarker cardiovascular blood test PREvent. This follows the February 16, 2012 press release announcing the completion of the clinical study demonstrating the extraordinary effectiveness of the test to predict risk of near-term (2-3 years) myocardial infarction, and death in patients with suspected or confirmed, insignificant or significant stable CAD. The clinical study and data was well received in an oral presentation, Beyond Courage: A Possible Strategy for Identifying the Stable CAD Patient at High Risk of MI or Death, by Dr. Stephen E. Epstein, Executive Director of the Cardiovascular Research Institute, MedStar Health Research Institute, at Cardiology Grand Rounds, Washington Hospital Center, Washington, D.C., on March 20, 2012.
The study revealed superior cardiac risk information by identifying the top 5% of CAD patients at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.
The initial results are reinforced by the additional findings, indicating very poor correlations between the levels of the test's individual biomarkers, suggesting that they are mainly independent of each other. The findings further indicate that the ability to risk strategize may improve by aggregating the results. Investigators found that regardless of whether patients were previously established into low, intermediate, or high
|SOURCE GenWay Biotech Inc.|
Copyright©2010 PR Newswire.
All rights reserved